Inactive Instrument

Company Alliqua Biomedical Inc Nasdaq

Equities

US0196212007

Biotechnology & Medical Research

Business Summary

Adynxx, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of a new class of therapeutics called transcription factor decoys and bringing to market disease-modifying products to address unmet needs in the treatment of pain and inflammation. The Company has leveraged its AYX platform of proprietary transcription factor decoys to identify and develop product candidates designed to modify the course of pain. Its product pipeline includes Brivoligide for postoperative pain and AYX2 for chronic pain. Brivoligide is a transcription factor decoy specifically designed to inhibit the function of transcription factor Early Growth Response 1 (EGR1), in the dorsal root ganglia (DRG), and spinal cord when administered at the time of surgery. Its second product candidate, AYX2, is a transcription factor decoy targeting the activity of specific members of the KLF family of transcription factors, including KLF6, KLF9 and KLF15.

Managers

Managers TitleAgeSince
Founder - 07-09-30
Chief Executive Officer - 10-11-30
Director of Finance/CFO - 09-12-31
Corporate Officer/Principal - 11-12-31

Members of the board

Members of the board TitleAgeSince
Director/Board Member 73 -
Director/Board Member - 07-12-31
Chairman 66 -
Chief Executive Officer - 10-11-30
Director/Board Member - 19-05-05
Founder - 07-09-30

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 5,807,877 5,807,877 ( 100.00 %) 0 100.00 %

Shareholders

NameEquities%Valuation
The Huntington National Bank (Columbus, Ohio)
0.000000 %
0 0.000000 % - $

Company contact information

Adynxx, Inc.

100 Pine Street Suite 500

94111, San Francisco

+

address Alliqua Biomedical Inc